TriAltus Bioscience Protein Purification Technology Supports Providence Cancer Institute COVID-19 Vaccine Development

Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute, are using TriAltus Bioscience, LLC protein purification technology to fast-track development of an ELISA test to monitor antibody responses to SARS-CoV-2 in patients that will receive a COVID-19 vaccine.

The researchers are using TriAltus’ ultra-high-affinity CL7/Im7 system to isolate and purify the Spike protein (S-protein) from SARS-COV2 (COVID-19) and bind it to ELISA plates.

Named for its distinctive spike, the S-protein helps the COVID-19 virus attach to and infect human cells, leading to COVID-19 infections.

“We’re in a race to develop this vaccine as quickly as possible, so it’s important to have technology that helps us isolate and purify the S-protein for time-critical research,” said Hong-Ming Hu, Ph.D., Associate Member, Cancer Immunobiology Laboratory, Earle A. Chiles Research Institute. “The CL7/Im7 system enables our lab to isolate and purify the spike protein faster, with higher yields, thus saving precious time.”

Chiles Research Institute researchers are fast-tracking the development of a COVID-19 vaccine in collaboration with biotech company OncoSec, UbiVac and the National Institutes of Health. If all goes as expected, vaccine trials could begin in May.

“It’s rewarding to know that our product can help expedite the search for a COVID-19 vaccine,” said TriAltus Bioscience CEO Bob Shufflebarger. “Our CL7/Im7 system is helping Dr. Hu and his colleagues attain high protein purity in a single-step process that saves critical time and boosts research productivity.”

Simple, reusable and resilient, TriAltus’ Activated Im7 Resin has been used to purify a variety of proteins – including membrane, multisubunit, coronavirus, and Cas9 and Cas12a CRISPR-associated proteins. The Im7 resin is capable of up to 100 reactivations without loss of activity.

The CL7 technology was invented by a team led by Dmitry Vassylyev, Ph.D., TriAltus co-founder and professor of biochemistry and molecular biology at the University of Alabama Birmingham (UAB). The foundational study was published in 2017 in the Proceedings of the National Academy of Sciences. TriAltus offers a limited free sample program for researchers to validate the CL7/Im7 system in their own labs.

 

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."